Bekämpfung von Mukoviszidose: Fortschritte in der CRISPR/Cas9-vermittelten Genkorrektur
**Auszug: Cystic Fibrosis Gene Correction Breakthroughs**
CRISPR/Cas9 gene editing holds immense promise for treating cystic fibrosis (CF) by correcting the underlying genetic defect. Recent advances have refined gene correction strategies, enhancing efficiency and precision. This article explores the latest developments in CRISPR/Cas9-mediated gene correction for CF, highlighting the potential to restore CFTR function and improve patient outcomes.






